

May 20, 2025

Press Release

TOWA PHARMACEUTICAL CO., LTD.

**Japan's first extended-release Rivastigmine transdermal formulation
(twice-weekly dosage),
"RIVALUEN® LA Patch 25.92 mg / 51.84 mg,"
launched and listed in the NHI drug price list**

Osaka, Japan, May 20, 2025 – Towa Pharmaceutical Co., Ltd. (Towa Pharmaceutical) is pleased to announce that Japan's first extended-release therapeutic patch for Alzheimer's type dementia, "RIVALUEN® LA Patch 25.92 mg / 51.84 mg" (nonproprietary name: Rivastigmine; hereinafter, "this drug"), has been listed in the National Health Insurance (NHI) Drug Price Standard on May 21, as announced in Japan's Official Gazette. This drug is scheduled to be released on May 28, 2025.

This drug is an extended-release transdermal patch (twice-weekly dosage) containing Rivastigmine as an API, developed by Luye Pharma Switzerland AG, a Swiss company. Towa Pharmaceutical obtained the license for this drug based on an exclusive development and sales agreement, and conducted a domestic Phase III clinical trial targeting mild to moderate Alzheimer's type dementia. Non-inferiority to a once-daily rivastigmine patch was demonstrated, and this drug was approved for manufacture and sales as a new drug on March 27, 2025 for the indication or efficacy of "suppression of progression of dementia symptoms in mild to moderate Alzheimer's type dementia" on March 27, 2025.

Patches are seen as a way to improve adherence since they provide a visual indication of medication status, and are expected to reduce the burden on caregivers who manage medication status. In contrast to current treatments for Alzheimer's type dementia, which require one or two doses daily, this drug reduces the dose frequency to twice weekly, and is thereby expected to further reduce the burden of medication management. Towa Pharmaceutical hopes that this drug will help realize sustainable dementia care and provide a novel treatment option for patients, their families, and those engaged in their care, thereby providing a better quality of life.

Under the Towa Philosophy, “We contribute to people's health. We are dedicated to people's genuine smiles,” we will continue to strive to become a company that is always needed by society and local communities, and to meet the needs of patients, caregivers, and medical professionals.

Overview of “RIVALUEN® LA Patch 25.92 mg / 51.84 mg”

Product name	RIVALUEN® LA Patch 25.92 mg / 51.84 mg
Nonproprietary name	Rivastigmine
Indication or efficacy	Suppression of progression of dementia symptoms in mild to moderate Alzheimer's type dementia
Dosage and administration	In general, for adults, administer 25.92 mg of Rivastigmine as a starting dose. Increase to 51.84 mg as a maintenance dose four weeks later, in principle. Apply the patch to normal healthy skin on the back, upper arm, or chest. In principle, apply a patch for four days at the start and replace the patch every three or four days (twice weekly).
Drug prices	25.92 mg 1 piece: 215.30 yen / 51.84 mg 1 piece: 329.00 yen
Date of approval for manufacture and sales	March 27, 2025
Date of listing in the drug price list	May 21, 2025
Release date	May 28, 2025
Manufacturer	Towa Pharmaceutical Co., Ltd.

[Reference information]

Manufacture and sales approval obtained for Japan's first extended-release Rivastigmine transdermal formulation (twice-weekly dosage),

“RIVALUEN® LA Patch 25.92 mg / 51.84 mg”

(Press release issued on March 27, 2025)

<https://www.towayakuhin.co.jp/assets/news250327.pdf>

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Email: kouhou@towayakuhin.co.jp